¹Ù·Î°¡±â ¸Þ´º

¹Ù·Î°¡±â ¸Þ´º º»¹®³»¿ë ¹Ù·Î°¡±â ¸ÞÀθ޴º ¹Ù·Î°¡±â

ÁÖ¿ä¾È³»

HOME »çÀÌÆ®¸Ê

FONT SIZE

ÆùƮũ±â Å°¿ò 100% 110% 120% 130% 140% ÆùƮũ±â ÁÙÀÓ
¸Þ´ºº¸±â
 
Á¦¸ñ
3/6 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
ÀÛ¼ºÀÏ
2021-03-05
Á¶È¸¼ö
264


¾È³çÇϼ¼¿ä, À̹øÁÖ ¹ßÇ¥ÀÚ ³ª·¡ÀÔ´Ï´Ù.

Á¦°¡ À̹øÁÖ ¹ßÇ¥ÇÏ°ÔµÉ ³í¹®Àº 2017³â cell reports¿¡ °ÔÀçµÈ ³í¹®À¸·Î Á¦¸ñÀº
"Biophysical attributes of CpG presentation control TLR9 signaling to differentially polarize systemic immune reponses"À̸ç,

PEI-PLGA¶ó´Â Micro- Nano particle¿¡ CpG¸¦ ·Îµù½ÃÄÑ Pathogen-like synthetic particle(PLP)¶ó ¸í¸íÇÑ ¹°ÁúÀ» ¸¸µé¾î º» ¹°ÁúÀÌ Dendritic cell ³»ºÎÀÇ signaling Àü´Þ ±âÀüÀ» ¹àÈ÷°í, »ç¿ëÇÑ particleÀÇ »çÀÌÁî ¶Ç´Â particle¿¡ ·ÎµùµÈ CpG density¿¡ µû¶ó T cellÀÇ ºÐÈ­¸¦ ´Ù¸£°Ô Á¶ÀýÇÑ´Ù´Â ³»¿ëÀ» ´ãÀº ³í¹®À¸·Î,

³í¹®ÀÌ ³ª¿ÂÁö Á¶±Ý ¿À·¡µÇ¾úÁö¸¸, ÃÖ±Ùµé¾î Á¦°¡ °ü½ÉÀ» °®°ÔµÈ CpG¿Í Nano adjuvant °ü·ÃÇÏ¿© °øºÎÇغ¸°íÀÚ ¼±Á¤ÇÏ¿´½À´Ï´Ù.

¿­½ÉÈ÷ ÁغñÇÏ¿© ³»ÀÏ ¹ßÇ¥Çϵµ·Ï ÇÏ°Ú½À´Ï´Ù.

³í¹® ¸µÅ©: https://pubmed.ncbi.nlm.nih.gov/28099848/
÷ºÎÆÄÀÏ:
÷ºÎÆÄÀÏÀÌ ¾ø½À´Ï´Ù.
´ÙÀ½±Û
3/6 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä ö±ÕÀÔ´Ï´Ù. À̹ø Åä¿äÀÏ ¼¼¹Ì³ª¿¡¼­ ¹ßÇ¥µå¸± ³í¹®ÀÇ Á¦¸ñÀº "SHP-1 regulates antigen cross-presentation and is exploited by Leishmania to evade immunity" À̸ç Áö³­ÇØ 12¿ù¿¡ cell report¿¡ ¹ßÇ¥ µÇ¾ú½À´Ï´Ù. ¼¼Æ÷³» ±â»ý ¼¼±ÕÀÎ Leishmanina °¡ ºÐºñÇÏ´Â ligand¸¦ ÀνÄÇÏ´Â Mincle ..
ÀÌÀü±Û
2/27 ¹ßÇ¥³í¹® ÀÔ´Ï´Ù
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä. À̹øÁÖ¿¡ Á¦°¡ ¹ßÇ¥ÇÒ ³í¹®Àº Mucosal immunology¿¡ 2020³â¿¡ ÃâÆÇµÈ 'Niche rather than origin dysregulates mucosal Langerhans cells development in aged mice' ÀÔ´Ï´Ù. º» ³í¹®¿¡¼­´Â epidermis¿¡ ºñÇÏ¿© ´ú ¾Ë·ÁÁø oral mucosa Langerhens cell¿¡ ´ëÇÏ¿© ¿¬±¸¸¦ ÇÏ¿´À¸¸ç ³ëÈ­¿¡ µû¸¥..